In Brief
Sharma, Ott, and colleagues show that expression of a key set of four transcription factors can reprogram hepatic myofibroblasts to induced hepatocyte-like cells in vivo and reduce liver fibrosis, suggesting that direct in vivo reprogramming may be an effective treatment approach for chronic liver disease.
SUMMARY
Direct induction of induced hepatocytes (iHeps) from fibroblasts holds potential as a strategy for regenerative medicine but until now has only been shown in culture settings. Here, we describe in vivo iHep formation using transcription factor induction and genetic fate tracing in mouse models of chronic liver disease. We show that ectopic expression of the transcription factors FOXA3, GATA4, HNF1A, and HNF4A from a polycistronic lentiviral vector converts mouse myofibroblasts into cells with a hepatocyte phenotype. In vivo expression of the same set of transcription factors from a p75 neurotrophin receptor peptide (p75NTRp)-tagged adenovirus enabled the generation of hepatocyte-like cells from myofibroblasts in fibrotic mouse livers and reduced liver fibrosis. We have therefore been able to convert pro-fibrogenic myofibroblasts in the liver into hepatocyte-like cells with positive functional benefits. This direct in vivo reprogramming approach may open new avenues for the treatment of chronic liver disease.
INTRODUCTION
The utility of transcription factors (TFs) for the acquisition of novel cell fates has been unlocked through landmark studies of induced pluripotent stem cell (iPSC) reprogramming (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) . Recently, by circumventing the pluripotent cell state, direct reprogramming of fibroblasts into neurons (Grande et al., 2013; Guo et al., 2014; Han et al., 2012; Kim et al., 2011; Lujan et al., 2012; Ring et al., 2012; Son et al., 2011; Su et al., 2014; Thier et al., 2012; Torper et al., 2013; Vierbuchen et al., 2010) , cardiomyocytes (Ieda et al., 2010; Qian et al., 2012) , and hepatocytes (Du et al., 2014; Huang et al., 2011 Huang et al., , 2014 Morris et al., 2014; Sekiya and Suzuki, 2011 ) through overexpression of specific TFs has been demonstrated. For example, functional neurons were generated from mouse fibroblasts by ectopic expression of Ascl1, Brn2, and Myt1l (Vierbuchen et al., 2010) . Similarly, a combination of three cardiacspecific TFs, Gata4, Mef2c, and Tbx5, directly reprogrammed mouse cardiac fibroblasts into cardiomyocyte-like cells in vitro and in vivo in a heart infarction model (Ieda et al., 2010; Song et al., 2012) . Lineage reprogramming of mouse fibroblasts into hepatocytes has been achieved in vitro by ectopic expression of HNF4A plus Foxa1, Foxa2 or Foxa3 or by the combination of Gata4, Hnf1a, and Foxa3 and inactivation of p19(Arf) in culture (Huang et al., 2011; Sekiya and Suzuki, 2011) . Recently, two other groups independently reprogrammed human fibroblasts into hepatocytes by forced ectopic expression of FOXA3, HNF1A, and HNF4A or the combination of HNF1A, HNF4A, and HNF6 together with the maturation factors ATF5, PROX1, and CEBPA (Du et al., 2014; Huang et al., 2014) . The direct conversion of fibroblasts into hepatocyte-like cells in vivo remains to be investigated, and the question needs to be addressed whether such an approach could also ameliorate the degree of fibrosis in damaged livers. (FOXA1, FOXA2, FOXA3, GATA4, HNF1A, HNF4A, and CEBPA) for direct reprogramming of myofibroblasts derived from primary hepatic stellate cells into hepatocytes. FOXA3, GATA4, HNF1A, and HNF4A transcription factors (4TFs) were selected for further experiments, since the absence of each of these TFs substantially reduced albumin secretion and CYP3A activity in our screening experiments ( Figure 1A ). To overexpress the selected 4TFs simultaneously, we cloned the cDNAs into a polycistronic lentiviral vector (henceforth referred to as LV.4TF) ( Figure 1B ).
In response to persistent inflammatory injuries large numbers of stellate cells, which have undergone ''activation'' to pro-fibrogenic myofibroblasts, accumulate in the liver. To harness the potential therapeutic effects of direct reprogramming in chronic liver disease, we first tested whether forced expression of 4TFs would induce a hepatocyte phenotype in cultured myofibroblasts ( Figure 1C ). The expression of 4TFs in transduced myofibroblasts was confirmed on day 4 by qRT-PCR ( Figure S1A ). Within 14 days after transduction, we observed profound changes in morphology of the transduced cells now resembling an epithelial phenotype ( Figure 1D ). To confirm the generation of hepatocytes from myofibroblasts, we transduced cells at day 10 with a reporter lentiviral vector, which expressed dTomato under transcriptional control of the albumin promoter ( Figure 1B ). Approximately 12% of the cells expressed dTomato, indicating the generation of iHeps ( Figures 1E and 1F) . We enriched dTomato protein expressing iHeps by fluorescence-activated cell sorting (FACS) for further characterization (Figures 1G-1K) . The iHeps showed expression, albeit at lower levels, of typical primary hepatocyte (Pr. Hc, cultured for 24 hr) markers and the downregulation of fibroblast genes ( Figures 1G, 1H , and S1B). Our principal-component analysis (PCA) analyses suggested that although iHeps acquired a hepatic gene expression profile, they remained a distinct cell type when compared to primary hepatocytes cultured for 24 hr. Importantly, iHeps exhibited functional characteristics of hepatocytes as they stored glycogen, showed uptake of low-density lipoprotein (LDL), secreted albumin, and acquired cytochrome P450 (CYP1A2 and 3A) activities (Figures 1I and 1J) . Genomic integrity was confirmed by arraybased comparative genomic hybridization (aCGH) analysis (Figure 1K) . Thus, ectopic expression of FOXA3, GATA4, HNF1A, and HNF4A converts myofibroblasts into iHeps in vitro.
Establishment of a Lineage-Tracing Model to Detect In Vivo Reprogramming
We next examined whether 4TFs expression would facilitate iHep formation in vivo. To investigate 4TFs-mediated lineage reprogramming in vivo, we developed a mouse model to detect iHeps derived from non-parenchymal cells (Figure 2A ). We used (Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP) mice (henceforth referred to as mT/mG). All cells including hepatocytes and non-parenchymal liver cells from these mT/mG mice express membrane-targeted tdTomato (mT) before Cre-mediated recombination (Muzumdar et al., 2007) (Figure 2B ). To label endogenous hepatocytes, adult mT/mG mice were injected intrasplenically with 4 3 10 11 adeno-associated virus (AAV) serotype 8 particles expressing Cre recombinase under transcriptional control of the liver-specific transthyretin (Ttr) promoter (Malato et al., 2011; Sharma et al., 2011) . As a result, membranous EGFP fluorescence in hepatocytes and tdTomato membranous fluorescence in non-parenchymal cells of the liver were expressed four weeks after AAV-Ttr-Cre injection ( Figure 2C ). Then, we induced myofibroblasts in the liver of AAV-Ttr-Cre-injected mT/mG mice by intraperitoneal injections of carbon tetrachloride (CCl 4 ) twice per week for a total of 8 weeks. These mice developed extensive fibrosis ( Figure 2D ) and accumulated myofibroblasts in the tissue. Notably, in these fibrotic livers, all non-parenchymal cells including myofibroblasts expressed tdTomato, whereas hepatocytes expressed EGFP ( Figure 2E ). To overexpress 4TFs in myofibroblasts, we designed a p75NTRp-tagged recombinant adenoviral vector (serotype 5), which expressed all 4TFs from a polycistronic transgene cassette. The adenoviral vector was modified to target mouse myofibroblasts through coupling of adenoviral fiber knobs with a peptide (single-chain antibody fragment) of the nerve growth factor (NGFp), which was selected for specific and high-affinity binding to the p75 neurotrophin receptor (p75NTR) present on hepatic stellate cells and myofibroblasts (Reetz et al., 2013) . Efficiency of vector targeting was tested in cell culture, as previously published (Reetz et al., 2013) (Figure S2A ). In vivo targeting of myofibroblasts by Ad.GFP-S11-NGFp was tested by injecting 5 3 10 9 adenoviral particles via the portal vein of fibrotic wildtype BALB/c mice as shown previously (Reetz et al., 2013) . The amount of injected virus particles was sufficient to transduce 30% of stellate cells in normal and 20% of myofibroblasts in CCl 4 -induced fibrotic livers of BALB/c mice. Predominantly, myofibroblasts were found to express EGFP in the liver of mice injected with Ad.GFP-S11-NGFp ( Figure 2F ), whereas control adenovirus vector injected mice showed transduction of hepatocytes ( Figure 2G ). Figure S2B ). Therefore, injection of Ad.GFP-S11-NGFp allows preferential targeting of myofibroblasts. Accordingly, one week after cessation of the CCl 4 treatment, we injected 5 3 10 9 p75NTRp-tagged Ad5.FOXA3. GATA4.HNF1A.HNF4A (henceforth referred to as Ad.4TF) via the portal vein of AAV-Ttr-Cre injected fibrotic wild-type BALB/c mice. This led to successful overexpression of 4TFs in sorted myofibroblasts from these mice within 4 days after injection (Figure 2H) . Importantly, Ad.4TF administration in normal BALB/c mice neither affected liver function tests nor histology ( Figure 2I ).
In Vivo iHep Formation via Direct Reprogramming
After establishing a model that faithfully identifies iHep formation, we examined iHep formation in mT/mG mice injected with AAV-Ttr-Cre followed by CCl 4 injections and subsequent administration of Ad.4TF. The control animals were treated exactly in the same manner, except for injection with empty adenoviral vector instead of Ad.4TF. In our lineage-tracing model, the endogenous hepatocytes would express membranous EGFP, while the iHeps could be detected by tdTomato positive membrane fluorescence ( Figure 2J ). To identify iHeps and distinguish them from endogenous hepatocytes, we stained liver tissues 30 days after Ad.4TF injection for albumin, major urinary protein (MUP), fumarylacetoacetate hydrolase (FAH), alpha-1 antitrypsin (AAT), and HNF4A, all characteristic hepatocyte markers in the liver. Immunofluorescence analyses of the liver harvested at 30 days after Ad.4TF injection showed albumin, MUP, FAH, AAT, and HNF4A expression mainly in endogenous hepatocytes with EGFP-positive membranes (Figures 2K and S2C) . However, few cells with tdTomato-positive membranes also stained positive for albumin, MUP, FAH, AAT, and HNF4A in the liver of Ad.4TF-injected mice. These tdTomatopositive cells that also stained positive for hepatocyte markers, either in clusters or as single cells, indicate the presence of iHeps. The control animals (n = 10), injected with empty adenoviral vector, did not express albumin, MUP, FAH, and AAT in any of the tdTomato-positive cells. The efficiency of direct reprogramming in vivo was calculated from the average of tdTomato-expressing cells, which stained positive for albumin, MUP, FAH, AAT, and HNF4A relative to the total hepatocyte population (n = 10 mice). The percentage of in-vivo-generated iHeps among the total hepatocyte population ranged from 0.2% to 1.2% in Ad.4TF-injected mice, whereas control mice did not show any reprogrammed cells ( Figure 2L ). Of note, we did not detect iHeps when Ad.4TF was administered in uninjured mice (data not shown). Since the number of myofibroblasts in fibrotic livers at 1 week after cessation of 8 weeks of CCL 4 treatment is between 15.4% and 21.7% of the total number of liver cells ( Figure S2D ), it can be estimated that 0.2% to 1.2% of iHeps detected in AD.4TF-injected mice is equivalent to a reprogramming efficiency of less than 4%. It is noteworthy to mention that reprogramming efficiency may be even lower than 4% if iHeps proliferate between the time when they appear and 30 days after Ad.4TF administration. Thus, our data indicate that expression of 4TFs in myofibroblasts facilitates the formation of iHeps in chronic liver disease.
Functional Analyses of In-Vivo-Generated iHeps One of the prerequisites for in-vivo-generated iHeps to be considered as hepatocytes is to possess the functions of mature hepatocytes. To characterize iHeps at the functional level, we isolated iHeps by Percoll density-gradient centrifugation followed by FACS from the liver of Ad.4TF-injected mice ( Figures   3A and 3B ). We did not find iHeps in control mice by FACS as well ( Figure S2E ). We specifically sorted for single-tdTomatopositive cells, because double-positive cells may represent endogenous cells that have not silenced tdTomato completely. The iHeps that were tdTomato positive, cultured for 24 hr, showed albumin secretion and urea synthesis similar to EGFPpositive endogenous hepatocytes (eHeps) ( Figures 3C and 3D ). The iHeps showed the ability to uptake indocyanine green (ICG); stained positive for oil red O, indicating the presence of triglycerides and lipids; stained positive for PAS, thus demonstrating the ability to store glycogen ( Figure 3E ); and exhibited (I) Hydroxyproline assay showed decreased levels of entire collagen content, measured in whole liver. (J) H&E, Sirius red, and immunohistochemical staining for desmin and p75NTR showed less fibrosis in Ad.4TF injected mice (n = 9) than respective controls (n = 9). Scale bars, 100 mM for H&E and desmin and 100 mM for Sirius red and p75NTR staining. cytochrome activity (CYP3A, 1A1, 2C9, and 1A2) similar to eHeps (Figure 3f ). Furthermore, we tested whether isolated iHeps are drug inducible. The treatment of iHeps with phenobarbital and rifampicin led to induction of Cyp1a1 (phase 1), Ugt1a1 (phase 2), Abcc2, and Oatp ( Figure 3G ). Importantly, the in-vivogenerated iHeps showed chromosomes with no obvious numerical or structural aberrations ( Figure S2F ) and the absence of exogenous 4TFs ( Figure S2G ), thus indicating the stable reprogramming of myofibroblasts into iHeps. In addition, Ki67 staining indicated that iHeps have the ability to proliferate in response to two-thirds partial hepatectomy in vivo ( Figure S2H ). Therefore, our thorough characterization suggests that in-vivo-generated iHeps possess functional properties of hepatocytes.
Overexpression of 4TFs Ameliorates Chemical-Induced Liver Fibrosis
To examine whether in vivo reprogramming ameliorates chronic liver disease, we determined the extent of liver fibrosis in CCl 4 -injected mice. First, qPCR showed lower levels of Col1a1 in the liver of Ad.4TF-injected mice, suggesting less liver fibrosis compared to respective controls ( Figure 3H ). Second, we performed hydroxyproline assay, which measures the entire collagen content of a liver. The Ad.4TF-injected mice showed significantly reduced levels of hydroxyproline, indicating decreased liver fibrosis ( Figure 3I ). In addition, histological grading of fibrosis, Sirius red staining, immunohistochemical staining of desmin and p75NTR, as well as serum levels of aminotransferases confirmed decreased liver fibrosis in Ad.4TF-injected mice compared to control mice ( Figures 3J-3L ). In addition, an 8-month follow-up study of mice injected with Ad.4TF showed normal histology and no signs of liver tumors ( Figure 3M ). Next, we tested whether injection of Ad.4TF during ongoing liver injury can lead to in vivo iHep formation and a reduction of liver fibrosis ( Figure 4A ). Indeed, we detected the presence of iHeps and less liver fibrosis in mice injected with Ad.4TF during an ongoing injury (Figures 4B-4E) . Hence, our results indicate that 4TFs-induced in vivo reprogramming ameliorates liver fibrosis in mice injected with CCl 4 for 8 weeks.
CCl 4 administration for up to 8 weeks induces a significant amount of liver fibrosis; however, it is still reversible. We therefore examined whether the forced expression of 4TF is capable of ameliorating liver injury in mice injected for 12 weeks with CCl 4 resembling an irreversible cirrhosis model ( Figure S3A ). Although, we detected the presence of iHeps, a beneficial effect on liver fibrosis was not observed in mice injected with Ad.4TF ( Figures S3B-S3F ). This might be due to the fact that the number of Ad.4TF reprogrammed iHeps in mice injected for 12 weeks with CCl 4 remained similar to those in mice injected for 8 weeks, whereas total myofibroblast numbers further increased after prolonged CCl 4 administration. This phenomenon can be explained, at least in part, by a modest but similar number of myofibroblasts transduced by Ad.4TF vector in both 8-week and 12-week CCl 4 models, but these were most likely outnumbered by the massive increase of fibrotic cells in the 12-week CCl 4 model.
Characterization of In-Vivo-Generated iHeps
To further prove the hepatic lineage identity of in vivo iHeps, we performed mRNA microarrays after pooling several livers isolated from different animals and compared them with myofibroblasts, myofibroblast-derived iHeps in vitro, and endogenous hepatocytes (eHeps, serving as positive control) in vivo. In silico analyses, such as hierarchical clustering and PCA, demonstrated that in vivo iHeps are more similar to eHeps than to in vitro iHeps ( Figures 5A and 5B ). This suggests that the in vivo hepatic environment further contributes to the maturation of in vivo iHeps.
The identity of reprogrammed cells can be faithfully determined by the CellNet platform with very high accuracy Morris et al., 2014) . We therefore extracted a list of genes comprising either the liver-typical or fibroblast-typical gene regulatory networks (GRNs) from CellNet and compared our in vivo or in vitro myofibroblast-derived iHeps ( Figure 5C ). In iHeps derived from myofibroblasts in vitro, 1,281 genes were upregulated by more than 4-fold and 1,576 genes were downregulated by more than 4-fold compared to 24-hr-cultured primary mouse hepatocytes. 22 (of 1,281) upregulated genes and 128 (of 1,576) downregulated genes were in common with the set of genes comprising the CellNet liver GRN. To assess genetic memory of myofibroblasts, we compared in vitro myofibroblast-derived iHeps with fibroblast GRN. Deregulated genes common with the fibroblast GRN included 184 (156 upregulated and 28 downregulated) genes. When in vivo iHeps were compared to in vivo eHeps (endogenous hepatocytes), a total of 426 genes were upregulated by more than 4-fold and 43 were downregulated by more than 4-fold. Only 8 (of 426) upregulated genes and 5 (of 43) downregulated genes were in common with the set of genes comprising the CellNet liver GRN. Deregulated genes common with the fibroblast GRN include 94 (94 upregulated and 0 downregulated) genes.
Deregulated genes (>4-fold up or down) in the in vitro iHeps derived from myofibroblasts thus represent 35% of the CellNet
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In vitro myofibroblast-derived iHep and PH24 (mouse hepatocytes that were 24 hours in culture) listed genes comprising the liver GRN. In contrast to the in-vitrogenerated iHeps, the in vivo iHeps show only 3.3% deregulated genes among the genes comprising the liver GRN. From these data, together with our thorough analyses of various liver metabolic functions, we conclude that the in vivo iHeps provide a similar liver GRN with only minor differences in 13 of 421 genes. In addition, we also provide evidence for (limited) genetic memory in a number of (myo)fibroblast GRNs.
Confirmation of iHep Formation in a Direct LineageTracing Model
Although, the AAV-Ttr-Cre-injected mT/mG model in combination with Ad.4TF is an appropriate model to detect iHeps in vivo, we examined the generation of iHeps in a second independent mouse model. To specifically detect myofibroblast-derived iHeps, we used mice expressing Cre under the transcriptional control of the lecithin-retinol acyltransferase (Lrat) promoter, which also contain the mT/mG transgenes ( Figure 6A ). LratCrebased lineage tracing has been shown to effectively trace myofibroblasts derived from the hepatic stellate cell (HSC) lineage (Mederacke et al., 2013) . We first confirmed the labeling of HSCs and myofibroblasts expressing EGFP in LratCre-mT/mG mice, consistent with a previous report (Mederacke et al., 2013) (Figures S4A and S4B) . We then examined the generation of iHeps after administration of Ad.4TF in mice injected for 8 weeks with hepatocytes ranging from 0.9% to 2.5% ( Figures 6B-6D and  S4C) . Notably, we did not find iHeps in control LratCre-mT/mG mice, as all of the isolated hepatocytes expressed tdTomato only ( Figure S4D ). All EGFP-positive cells were myofibroblasts ( Figure S4E ). Furthermore, sorted in vivo iHeps exhibited functional characteristics similar to endogenous hepatocytes (Figures 6E-6J ). In addition, isolated iHeps expressed hepatocyte markers (Fah, Ck18, Hnf4a, Hnf1a, Gjb1, Ck8 , and Apoa1), but not the myofibroblast markers (Acta1, Col1a1, and Col2a1) or an intestinal marker (Cdx2) ( Figure S4F ). Importantly, in vivo iHeps possess the ability to proliferate in response to stimuli such as epidermal growth factor, in vitro ( Figure S4G ), or after two-thirds partial hepatectomy in vivo ( Figure S4H ). These iHeps regulated expression of genes involved in glucose metabolism such as G6pc and Pck1 (Figures S4I and S4J) , and more importantly, glucose levels upon treatment with glucagon and insulin ( Figures S4K and S4L) . Thus, our findings in the LratCremT/mG model confirm that forced expression of 4TFs in myofibroblasts generates functional iHeps in vivo.
Demonstration of iHep Formation in a CholestasisInduced Liver Fibrosis Model
To rule out whether formation of in vivo iHeps is restricted to only CCl 4 -induced liver fibrosis, we investigated this phenomenon in a well-established cholestasis-induced liver fibrosis model. To address this, we analyzed iHep formation in LratCre-mT/mG mice fed an 3.5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet ( Figure 7A ). Similar to the CCl 4 model, we detected iHeps that express EGFP and hepatocyte markers in mice injected with Ad.4TF (Figures 7B and 7C) . We then evaluated the effect of overexpression of 4TFs on DDC-induced fibrosis and characterized those iHeps similar to CCl 4 -induced liver fibrosis. Col1a1 expression analyses, hydroxyproline content, and Sirius red and desmin staining revealed the reduced fibrosis in 4TFs overexpressing mice (Figures 7D-7F) . Furthermore, iHeps isolated from the DDC model also showed the functional characteristics of hepatocytes ( Figures 7G-7I) . Therefore, in vivo iHep formation can be induced by overexpression of 4TFs in the DDC model, and 4TFs overexpression ameliorates DDC-induced fibrosis.
In-Vivo-Generated iHeps Lack Any Fibrolytic Activity In order to determine whether in-vivo-generated iHeps exert any direct fibrolytic effect, we co-cultured sorted eHeps or iHeps from LratCre-mT/mG mice with the Col-GFP hepatic stellate cell line. Unchanged mRNA expression of myofibroblast markers, such as Acta1, Col1a1, and Col2a1, suggests that in-vivo-generated iHeps were unable to suppress activation of stellate cells ( Figure S4M ). It further indicates that the observed reduction in fibrosis was due to decreased number of myofibroblasts rather than a fibrolytic effect of in-vivo-generated iHeps.
Ad.4TF-Based Reprogramming Does Not Give Rise to Cells Other Than iHeps
To assess whether other types of liver cells are produced via in vivo reprogramming, we stained livers for SOX9 (a liver stem/progenitor cell marker), CK19 (a bile duct and liver stem/progenitor cell marker), and MIC1 (an oval cell marker). Immunofluorescence analyses showed the absence of positive staining for any of the above-mentioned markers in cells with EGFP-positive membranes in the Ad.4TF-administered, CCl 4 -treated, LratCre-mT/mG model ( Figure S5 ). Thus, we confirmed that Ad.4TF injection in fibrotic livers leads to formation of iHeps in vivo without forming cholangiocytes or liver stem/progenitor cells.
Since p75NTR is also expressed in tissues other than fibrotic livers, we also considered the possibility whether Ad.4TF administration converts cells of other organs into iHeps. However, our immunofluorescence staining for albumin and HNF4A revealed absence of positive cells in the brain, heart, lung, and kidney (Figure S6) . Thus, our results indicate the absence of iHeps formation in organs other than the liver.
In-Vivo-Generated iHeps Are Not the Result of Cell Fusion Next, we sought to investigate whether in-vivo-generated iHeps could be a result of cell fusion. To address this, we stained unsorted iHeps and eHeps, isolated from LratCre-mT/mG mice, for p75NTR, a myofibroblast-specific marker. By analyzing immunofluorescence stainings on more than 1,000 iHeps, we could not detect any iHeps, which were also positive for p75NTR ( Figure S7 ). Furthermore, our aCGH analyses of invivo-generated iHeps did not show any increase in ploidy compared to equal DNA amounts of eHeps used as the reference sample ( Figure S2F ), thus suggesting absence of cell fusion. Together, these data suggest that in-vivo-generated iHeps are the result of direct reprogramming rather than cell fusion events.
DISCUSSION
Our findings indicate that simultaneous expression of FOXA3, GATA4, HNF1A, and HNF4A can reprogram mouse myofibroblasts into cells with a hepatocyte-like phenotype. Targeted, cell-type-specific expression of the TFs in mice results in a phenotype change of liver myofibroblasts into hepatic cells, which triggers tissue remodeling in chronic liver failure. Degradation of extracellular matrix, a decrease in myofibroblast numbers, and hepatocyte proliferation are considered necessary steps for effective resolution of fibrosis and recovery of the liver Kendall et al., 2009) . Hence, the conversion of profibrogenic myofibroblasts into hepatocyte-like cells would not only attenuate the development of fibrosis but also improve liver function in chronic liver failure. Indeed, we provide evidence for amelioration of liver fibrosis following up to 8 weeks of CCl 4 treatment in mice with iHeps. The observed amelioration of liver fibrosis by reprogramming of myofibroblasts into iHeps in vivo can be explained by two synergistic effects. On one hand, conversion of certain numbers of myofibroblasts, the major contributor of liver fibrosis, into iHeps, reduces the number of pro-fibrogenic myofibroblasts. In fact, reduced numbers of myofibroblasts can indeed ameliorate liver fibrosis (Puche et al., 2013) . Notably, in both lineage-tracing mouse models, iHeps often appeared near the portal vein or central vein regions. Therefore, it is possible that a few iHeps may be generated from perivascular mesenchymal cells, including portal fibroblasts, smooth muscle cells around the portal vein, and fibroblasts around the central vein. On the other hand, generation of numerous new iHeps, which possess functional characteristics of primary hepatocytes, restores the deteriorating liver function that is frequently observed during liver fibrosis.
There are a few unanswered questions that would require future studies to address them. First, it remains unclear why iHeps were detected only in fibrotic livers and not in normal mice. A plausible explanation is that quiescent HSCs present in normal liver express p75NTR at very low levels compared to its very high expression in myofibroblasts seen in fibrotic livers. This may, in turn, lead to suboptimal expression of 4TF in quiescent HSCs compared to their optimal expression in myofibroblasts. Additionally, the fibrotic milieu may also facilitate generation of iHeps from myofibroblasts.
Second, it remains a possibility that iHeps are formed via an intermediate stage that resembles liver progenitor cells. A comprehensive characterization of iHeps between the time when they first appear and 30 days after Ad.4TF administration would not only answer whether iHeps are generated via a progenitor stage but also uncover key regulatory pathways involved in iHep formation.
Third, we cannot rule out the possibility that overexpression of 4TFs in endogenous hepatocytes may contribute to reduction in fibrosis, since overexpression of HNF4A in hepatocytes has recently been suggested to revert long-term CCl 4 induced damage in a rat model (Nishikawa et al., 2015) . Our data, however, indicate that the direct conversion of myofibroblasts into hepatocyte-like cells is the more prominent factor in our experimental setup, since the delivery of 4TFs was preferentially targeted to myofibroblasts. The modest transduction efficiency of myofibroblasts in our in vivo experiments might explain the observation that amelioration of liver fibrosis (8-week CCl 4 ), but not of cirrhosis (12-week CCl 4 ), was detectable. This latter finding can be attributed to a higher total number of myofibroblasts in cirrhotic livers, from which only a limited number (similar to that in fibrotic livers) was efficiently transduced.
In summary, our study demonstrates the direct conversion of pro-fibrogenic myofibroblasts in vivo into hepatocyte-like cells in the liver and shows that this can indeed ameliorate fibrosis in damaged livers. This approach provides a promising therapeutic potential for the treatment of chronic liver disease. Therefore, future studies should be aimed to enhance the efficiency of iHep generation through improvement in targeted transduction in order to provide beneficial therapeutic effects through iHep formation in more advanced liver fibrosis.
EXPERIMENTAL PROCEDURES
Animals 12-week-old BALB/c and mT/mG (Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP) mice were obtained from Charles River Laboratories and Jackson Laboratory, respectively. Lrat-Cre transgenic mice were kindly provided by Robert Schwabe (Columbia University, New York, NY). To induce liver fibrosis, mice were injected with 4 ml/g 10% CCl 4 dissolved in corn oil. To induce cholestasis-induced liver fibrosis, LratCre-mT/mG mice were fed a DDC diet. The use of animals for this study was approved by the Institutional Animal Care and Use Committee of the Hannover Medical School.
Lentivirus Expression Plasmids
Third-generation self-inactivating VSV-G lentiviral vectors were derived from the vector backbone pRRL.PPT.SF.pre* (Maetzig et al., 2011; Schambach et al., 2006) . The human cDNAs of the TFs FOXA3, GATA4, HNF1A, and HNF4A were cloned together into the pRRL.PPT.SF.pre* plasmid. The cDNAs were separated by proteolytic cleavage sites. All 2A sites and the HNF4A cDNA were codon optimized according to favored human tRNA codons (Genscript). This process improves translatability and mRNA half-life and removes cryptic splice and poly(A) sites. For the reporter construct, a dTomato reporter gene was cloned under the transcriptional control of minimal albumin promoter/enhancer sequence.
Lineage Reprogramming 1 3 10 5 primary mouse myofibroblasts cells were transduced with lentiviral vector encoding for 4TFs at MOI 5. One day after transduction, complete DMEM medium was replaced by HCM medium. On day 10, cells were transduced with reporter lentiviral vector before trypsinization and reseeding them on collagen-coated dishes the next day. Afterward, cells were maintained in HCM medium. Medium was changed every 2 days. 14 days after first transduction, the cells were tested for protein secretion and CYP activity or harvested for mRNA isolation.
Generation of Recombinant Adeno-Associated Virus and Adenovirus Vectors AAV8.Ttr.Cre vector was prepared as described previously (Sharma et al., 2011) . Adenovirus serotype-5-derived wild-type vector (Ad.GFP) expressing GFP and Ad5.FOXA3.GATA4.HNF1A.HNF4A expressing the 4TFs were generated by homologous recombination following cotransfection with pAdEasy1 in E. coli BJ5183. Ad vectors were propagated in HEK293 cells, purified by CsCl buoyant density centrifugation, and measured at an optical density of 260. Peptide coupling and titration of the vectors were performed as previously described (Reetz et al., 2013 Prior to the reverse transcription reaction, 1 ml of a 1:5,000 dilution of Agilent's One-Color spike-in Kit stock solution (#5188-5282, Agilent Technologies) was added to 100 ng total RNA of each analyzed sample. The cRNA fragmentation, hybridization, and washing steps were carried out according to Agilent's One-Color Microarray-Based Gene Expression Analysis Protocol V5.7, except that 500 ng of each labeled cRNA sample was used for hybridization. Slides were scanned on the Agilent Micro Array Scanner G2565 CA (pixel resolution 5 mm, bit depth 20). Data extraction was performed with the Feature Extraction Software V10.7.3.1.
Statistical Analyses
Significance was determined with two-tailed, two-sample equal variance Student's t test. A p value of < 0.05 was considered as significant. Error bars represent ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0005.
